# Theravance Biopharma Inc (TBPH)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/TBPH/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 17.70M | $ -4.93M | $ 73.28M | $ 73.30M | $ 290.59M |
| 2025 | $ 110.03M | $ 108.43M | $ 244.20M | $ 75.50M | $ 296.72M |
| 2024 | $ 67.67M | $ -59.30M | $ -12.47M | $ 49.82M | $ 175.55M |
| 2023 | $ 62.09M | $ -59.68M | $ -31.88M | $ 49.16M | $ 213.00M |
| 2022 | $ 57.36M | $ 974.26M | $ -209.53M | $ 52.16M | $ 441.80M |
| 2021 | $ 65.75M | $ -237.05M | $ -251.12M | $ 669.52M | $ -338.57M |
| 2020 | $ 91.54M | $ -354.17M | $ -327.42M | $ 676.26M | $ -303.75M |
| 2019 | $ 94.76M | $ -305.20M | $ -311.55M | $ 510.53M | $ -223.84M |
| 2018 | $ 79.73M | $ -284.64M | $ -158.62M | $ 454.35M | $ -51.59M |
| 2017 | $ 20.73M | $ -384.48M | $ -274.09M | $ 223.75M | $ 115.18M |
| 2016 | $ 66.93M | $ -262.33M | $ -139.13M | $ 222.68M | $ 350.23M |
| 2015 | $ 59.15M | $ -255.84M | $ -240.80M | $ 0 | $ 243.07M |
| 2014 | $ 16.52M | $ -334.94M | $ -251.89M | $ 0 | $ 289.79M |
| 2013 | $ 321.4K | $ -222.27M | $ -175.92M | $ 0 | $ -17.04M |
| 2012 | $ 6.46M | $ -89.19M | $ -69.81M | $ 0 | $ -6.99M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.25 |
| Liabilities / Eq | 0.63 |
| Current Ratio | 13.14 |

## Other views

- [Metrics](https://sponda.capital/en/TBPH.md)
- [Charts](https://sponda.capital/en/TBPH/charts.md)
- [Compare](https://sponda.capital/en/TBPH/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-13.